A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

Abstract De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is the focus of international research efforts. However, the feasibility of this approach and its appe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer
Formato: Artigo
Idioma:Inglês
Publicado: Nature Portfolio 2022-05-01
Series:npj Breast Cancer
Acceso en liña:https://doi.org/10.1038/s41523-022-00429-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares